Intetics Is Recognized as Inc. 2023 Power Partner Awards Honoree in the AI & Data Category
October 25, 2023 06:01 ET
|
Intetics Inc.
Inc. named Intetics an honoree on the 2023 Power Partner Awards list in the Artificial Intelligence & Data category.
MarginEdge Recognized by Inc.’s Power Partner Awards and Washington Business Journal’s Fastest Growing Companies 2023
October 24, 2023 08:00 ET
|
MarginEdge
ARLINGTON, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- MarginEdge, the leading restaurant management and bill payment platform, today announced it has been recognized by the 2023 Inc. Power Partners...
Text Request Honored with Inc. Power Partner Award for 2nd Year
October 24, 2023 07:33 ET
|
Text Request
CHATTANOOGA, TENN., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Text Request, the industry-leading business messaging platform, has been recognized as an Inc. Power Partner for the second year in a row....
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
August 28, 2023 07:00 ET
|
ONL Therapeutics
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery Topline data readout...
Barrack, Rodos & Bacine Investigates Napco Security Technologies, Inc. (NSSC)
August 24, 2023 09:30 ET
|
Barrack Rodos & Bacine
PHILADELPHIA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Napco Security Technologies, Inc. (“Napco”) (NASDAQ: NSSC) for potential violations of federal...
EQUITY ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Edgio, Inc. f/k/a Limelight Networks, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGIO, LLNW
April 27, 2023 12:23 ET
|
The Rosen Law Firm PA
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edgio,...
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
April 12, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 11, 2023 07:00 ET
|
ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
April 04, 2023 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
March 08, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...